Cure of Alzheimer’s Dementia Requires Addressing All of the Affected Brain Cell Types
Open Access
- 4 March 2023
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (5) , 2049
Abstract
Multiple genetic, metabolic, and environmental abnormalities are known to contribute to the pathogenesis of Alzheimer’s dementia (AD). If all of those abnormalities were addressed it should be possible to reverse the dementia; however, that would require a suffocating volume of drugs. Nevertheless, the problem may be simplified by using available data to address, instead, the brain cells whose functions become changed as a result of the abnormalities, because at least eleven drugs are available from which to formulate a rational therapy to correct those changes. The affected brain cell types are astrocytes, oligodendrocytes, neurons, endothelial cells/pericytes, and microglia. The available drugs include clemastine, dantrolene, erythropoietin, fingolimod, fluoxetine, lithium, memantine, minocycline, pioglitazone, piracetam, and riluzole. This article describes the ways by which the individual cell types contribute to AD’s pathogenesis and how each of the drugs corrects the changes in the cell types. All five of the cell types may be involved in the pathogenesis of AD; of the 11 drugs, fingolimod, fluoxetine, lithium, memantine, and pioglitazone, each address all five of the cell types. Fingolimod only slightly addresses endothelial cells, and memantine is the weakest of the remaining four. Low doses of either two or three drugs are suggested in order to minimize the likelihood of toxicity and drug–drug interactions (including drugs used for co-morbidities). Suggested two-drug combinations are pioglitazone plus lithium and pioglitazone plus fluoxetine; a three-drug combination could add either clemastine or memantine. Clinical trials are required to validate that the suggest combinations may reverse AD.Keywords
This publication has 174 references indexed in Scilit:
- Cerebral Microinfarcts: A Systematic Review of Neuropathological StudiesJournal of Cerebral Blood Flow & Metabolism, 2012
- Fluoxetine protects neurons against microglial activation-mediated neurotoxicityParkinsonism & Related Disorders, 2012
- Scavenger receptor CD36 is essential for the cerebrovascular oxidative stress and neurovascular dysfunction induced by amyloid-βProceedings of the National Academy of Sciences, 2011
- Disrupted energy metabolism and neuronal circuit dysfunction in cognitive impairment and Alzheimer's diseaseThe Lancet Neurology, 2011
- FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P 1 ) modulationProceedings of the National Academy of Sciences, 2010
- Regulation of GABAergic synapse formation and plasticity by GSK3β-dependent phosphorylation of gephyrinProceedings of the National Academy of Sciences, 2010
- Erythropoietin promotes hippocampal neurogenesis in in vitro models of neonatal strokeNeurobiology of Disease, 2010
- Dantrolene: Mechanisms of Neuroprotection and Possible Clinical Applications in the Neurointensive Care UnitNeurocritical Care, 2008
- Lithium delays progression of amyotrophic lateral sclerosisProceedings of the National Academy of Sciences, 2008
- Effects of memantine on mitochondrial functionBiochemical Pharmacology, 2008